Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 14
1986 43
1987 95
1988 121
1989 150
1990 177
1991 249
1992 240
1993 262
1994 267
1995 283
1996 220
1997 206
1998 187
1999 204
2000 205
2001 204
2002 208
2003 210
2004 214
2005 214
2006 280
2007 317
2008 313
2009 311
2010 342
2011 472
2012 572
2013 557
2014 506
2015 446
2016 387
2017 359
2018 263
2019 86
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

8,484 results
Results by year
Filters applied: . Clear all
Page 1
DNA Vaccines: Regulatory Considerations and Safety Aspects
Myhr AI. Curr Issues Mol Biol 2017 - Review. PMID 27705898 Free article.
In addition the main safety concerns associated with DNA vaccines, relating to unwanted side effects in the vaccinated mammal or fish, are presented. ...
In addition the main safety concerns associated with DNA vaccines, relating to unwanted side effects in the vaccinated mammal or fish …
Side effects of cytokines approved for therapy.
Baldo BA. Drug Saf 2014 - Review. PMID 25270293
Underlying each adverse events profile is their pleiotropism, potency and capacity to release other cytokines producing cytokine 'cocktails'. Side effects, some serious, occur despite cytokines being endogenous proteins, and this therefore demands caution in attempts to introduce individual members into the clinic. ...
Underlying each adverse events profile is their pleiotropism, potency and capacity to release other cytokines producing cytokine 'coc …
Aflibercept
Stewart MW, et al. Nat Rev Drug Discov 2012. PMID 22460118
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration....
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular …
Erythropoietin
Romijn JA. N Engl J Med 1991. PMID 1891030
Acute Toxicity of the Recombinant and Native Phα1β Toxin: New Analgesic from Phoneutria nigriventer Spider Venom.
Dallegrave E, et al. Toxins (Basel) 2018. PMID 30545036 Free PMC article.
Phα1β, a purified peptide from the venom of the spider Phoneutria nigriventer, and its recombinant form CTK 01512-2 are voltage-dependent calcium channel (Ca(V)) blockers of types N, R, P/Q, and L with a preference for type N. ...The aim of this study was to evaluate the acute intrathecal toxicity of the native and recombinant Phα1β toxin in Wistar rats. ...
Phα1β, a purified peptide from the venom of the spider Phoneutria nigriventer, and its recombinant form CTK 01512-2 are voltage-depen …
Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
Okeke MI, et al. Viruses 2017 - Review. PMID 29109380 Free PMC article.
The use of MVA and MVA-vectored vaccines against human and animal diseases must comply with regulatory requirements as they pertain to environmental risk assessment, particularly the characterization of potential adverse effects to humans, animals and the environment. ...These will contribute to improved risk assessment of MVA and recombinant MVA vaccines....
The use of MVA and MVA-vectored vaccines against human and animal diseases must comply with regulatory requirements as they pertain to envir …
Safety of the Bacillus thuringiensis-derived Cry1A.105 protein: Evidence that domain exchange preserves mode of action and safety
Wang C, et al. Regul Toxicol Pharmacol 2018. PMID 30196079 Free article.
Like its intact donor proteins, Cry1A.105 was heat labile at temperatures ≥75 °C and degraded upon exposure to gastrointestinal proteases. No adverse effects were observed in mice when Cry1A.105 was dosed orally at 2451 mg/kg body weight. Therefore, the weight of evidence supports that Cry1A.105 is safe for human and animal consumption. ...
Like its intact donor proteins, Cry1A.105 was heat labile at temperatures ≥75 °C and degraded upon exposure to gastrointestinal prote …
8,484 results
Jump to page
Feedback